• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Consumer groups, medical device makers spar during MDUFMA III hearings

Consumer groups, medical device makers spar during MDUFMA III hearings

February 15, 2012 By MassDevice staff

FDA investigation

Consumer advocacy groups urged the U.S. House of Representatives to take a stronger hand in promoting safety in medical devices during a hearing today on the re-authorization of the medical device user fee act.

Industry officials and venture capitalists highlighted the role the med-tech sector plays in creating high-paying jobs and generating innovative, life-saving products. Consumer advocates were having none of that, chiding the user fee negotiations for putting safety on the back burner under pressure for faster review times.

The latest agreement between the FDA and the device industry on the third go-around for the user fee program proposes to collect $595 million over 5 years, double the amount agreed to in the previous generation of the Medical Device User Fee & Modernization Act, but some say that’s not enough.

"During the course of negotiations with industry, the FDA indicated that it needed resources of between $770 million to $1.15 billion to implement the performance goals desired by industry," Lisa Swirsky, senior policy analyst at patient advocacy group Consumers Union, told members of the House Energy & Commerce Committee’s Subcommittee on Health this morning. "The fees paid by medical device makers are currently so modest that even doubling of the fees is a small price to pay when considering that these devices may make companies millions to billions of dollars."

Device makers and stakeholders weren’t quite so optimistic, warning the panel that America’s place as the global leader in medical technology depends on maintaining a swift and effective FDA.

"While we are making progress in improving patient care and see immense future opportunities to provide jobs and contribute to long-term economic growth, we are also worried," David Perez, Terumo BCT president & CEO and AdvaMed board member, told House members. "Delays in product approval, inconsistency in the review process, and the resulting downstream effects on investment and innovation have undermined the competitiveness of our industry and harmed patient access to new treatments, diagnostics, and cures.”

"Today, America is the world leader in medical technology. But there are warning signs." Perez added. "A key factor in our loss of competitiveness has been the decline in the FDA’s performance in ensuring timely patient access to safe and effective medical devices."

Device lobby AdvaMed has praised the user fee plan that it and other device groups signed off on with the FDA, with AdvaMed president & CEO Stephen Ubl calling the deal a “game-changer” for both the agency and the industry.

"We believe the agreement will accelerate the development and approval of safe and effective treatments and diagnostics, helping FDA, industry and most importantly, patients," Ubl said in prepared remarks. "We believe it is in the interests of patients and the American economy that this agreement functions well, and we will work with FDA to help make that happen."

Consumer Union’s Swirsky had little love for the concord between industry and the federal watchdog agency.

"The word ‘safety’ does not appear once in the minutes from the meeting where industry and FDA came to agreement," she said in testimony today. "At a time when the device industry has seen large-scale safety failures of some of it products, such as surgical mesh and metal-on-metal hips, it is troubling that the main focus of conversations between industry and the agency that regulates it is on speeding up review times."

Consumer Union, the policy and advocacy arm of Consumer Reports, petitioned the FDA last week to implement more stringent oversight of medical devices in the new user fee agreements, to prevent the public from being used "as guinea pigs when it comes to something as important as a medical implant."

Filed Under: Food & Drug Administration (FDA), News Well Tagged With: AdvaMed, Consumers Union, MDUFMA, Terumo

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy